Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Drachman

Showing results (281-290 of 581) with videos related to

Pageof 59
Sort By:
Annals of Neurology|August 1, 1983
Combined short-term immunotherapy for experimental autoimmune myasthenia gravisA Pestronk, D B Drachman, R Teoh, et al.
Archives of Neurology|December 1, 1987
Vacuolar change in Alzheimer's diseaseT W Smith, U Anwer, U DeGirolami, et al.
Experimental Neurology|January 1, 1988
Effect of ketoleucine treatment on atrophy of skeletal muscleW C Yee, D B Drachman, M Walser, et al.
Clinical Immunology and Immunopathology|February 1, 1985
Treatment of experimental myasthenia gravis with cyclosporin AD B Drachman, R N Adams, K McIntosh, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1993
3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptorsR W Kuncl, D B Drachman, R Adams, et al.
Neurology|January 1, 1989
Thalamic dementia and motor neuron diseaseF Deymeer, T W Smith, U DeGirolami, et al.
Leukemia|May 10, 2000
CDP/Cut DNA binding activity is down-modulated in granulocytes, macrophages and erythrocytes but remains elevated in differentiating megakaryocytesN Martin-Soudant, J G Drachman, K Kaushansky, et al.
Toxins|November 10, 2011
Strategy for treating motor neuron diseases using a fusion protein of botulinum toxin binding domain and streptavidin for viral vector access: work in progressDaniel B Drachman, Robert N Adams, Uma Balasubramanian, et al.
Postgraduate Medical Journal|November 24, 1999
Myocardial infarction, seizure and an abnormal head CT scanN Selvaraj, D A Drachman, P Ravin, et al.
Science (New York, N.Y.)|February 17, 1984
Susceptibility of skeletal muscle to Coxsackie A2 virus infection: effects of botulinum toxin and denervationC G Andrew, D B Drachman, A Pestronk, et al.
Pageof 59

Showing results (281-290 of 581) with videos related to

Sort By:
Pageof 59
Annals of Neurology|August 1, 1983
Combined short-term immunotherapy for experimental autoimmune myasthenia gravisA Pestronk, D B Drachman, R Teoh, et al.
Archives of Neurology|December 1, 1987
Vacuolar change in Alzheimer's diseaseT W Smith, U Anwer, U DeGirolami, et al.
Experimental Neurology|January 1, 1988
Effect of ketoleucine treatment on atrophy of skeletal muscleW C Yee, D B Drachman, M Walser, et al.
Clinical Immunology and Immunopathology|February 1, 1985
Treatment of experimental myasthenia gravis with cyclosporin AD B Drachman, R N Adams, K McIntosh, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1993
3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptorsR W Kuncl, D B Drachman, R Adams, et al.
Neurology|January 1, 1989
Thalamic dementia and motor neuron diseaseF Deymeer, T W Smith, U DeGirolami, et al.
Leukemia|May 10, 2000
CDP/Cut DNA binding activity is down-modulated in granulocytes, macrophages and erythrocytes but remains elevated in differentiating megakaryocytesN Martin-Soudant, J G Drachman, K Kaushansky, et al.
Toxins|November 10, 2011
Strategy for treating motor neuron diseases using a fusion protein of botulinum toxin binding domain and streptavidin for viral vector access: work in progressDaniel B Drachman, Robert N Adams, Uma Balasubramanian, et al.
Postgraduate Medical Journal|November 24, 1999
Myocardial infarction, seizure and an abnormal head CT scanN Selvaraj, D A Drachman, P Ravin, et al.
Science (New York, N.Y.)|February 17, 1984
Susceptibility of skeletal muscle to Coxsackie A2 virus infection: effects of botulinum toxin and denervationC G Andrew, D B Drachman, A Pestronk, et al.
Pageof 59